This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Drug treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Drug therapy dependent on concomitant factors:

  • if left ventricular failure then a loop diuretic and nifedipine 10-20 mg/8h.
  • suspected phaeochromocytoma: labetalol 20-200 mg 24 hourly.
  • if beta-blockers are contra-indicated then nifedipine 10-20 mg/8h. Blood pressure should fall gently after approximately 30 minutes.
  • if beta-blockers not contra-indicated then atenolol 50-100 mg once daily.

If patient requires minute-by-minute control of blood pressure, for example during a seizure, then use sodium nitroprusside. Give 0.3-8 mcg / kg / min IVI in 5% dextrose, for example 50 mg nitroprusside in one litre of dextrose 5%. Should expect to give at 100-200 ml/h. Titrate the dose against regular blood pressure. Aim for a diastolic of 100-110 mmHg. To prevent photodeactivation cover the burette with reflective foil.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.